Tirzepatide improves sleep quality and fatigue - SURMOUNT-OSA findings

TL;DR

A patient-reported outcomes analysis from the SURMOUNT-OSA trial found that tirzepatide (Mounjaro/Zepbound) significantly improved sleep disturbance, sleep-related impairment, fatigue, and health-related quality of life in people with obesity and moderate-to-severe obstructive sleep apnea at 52 weeks. These improvements went beyond the objective airway metrics that made the original headlines - and they matter because poor sleep is one of the most underappreciated drivers of weight gain and metabolic dysfunction in GLP-1 users.

The original SURMOUNT-OSA trial results made news in late 2024 when tirzepatide received FDA approval for obstructive sleep apnea - the first GLP-1 medication to gain this indication. The published data focused on objective measures: the apnea-hypopnea index (AHI), which counts the number of breathing interruptions per hour. Tirzepatide reduced AHI dramatically, by roughly 55-63% across the two studies.

But the AHI tells you what is happening to your airway at night. It does not tell you how you feel during the day - whether you have energy, whether you can concentrate, whether you feel like a functional person again after years of fragmented sleep. The patient-reported outcomes (PRO) analysis published in Sleep Medicine in 2025 fills in that picture, and the results are significant.

What the SURMOUNT-OSA PRO analysis measured

The study analysed patient-reported outcomes from 469 participants across both SURMOUNT-OSA trials - 234 in Study 1 (where participants used tirzepatide without PAP therapy) and 235 in Study 2 (where some participants continued PAP therapy alongside tirzepatide). All participants had moderate-to-severe obstructive sleep apnea (OSA) and obesity (BMI ≥30 kg/m²).

The PRO tools used were:

• PROMIS Sleep Disturbance and PROMIS Sleep-related Impairment scales - validated measures of how disrupted sleep affects daily functioning
• Epworth Sleepiness Scale (ESS) - a standard measure of daytime sleepiness
• Functional Outcomes of Sleep Questionnaire (FOSQ) - measures how sleep affects daily activities and functioning
• SF-36v2 - a general health-related quality of life instrument
• EQ-5D-5L - a standardised health state measure used widely in health economics
• Patient Global Impression (PGI) scales - asking patients directly about fatigue, sleepiness, snoring, and sleep quality

Follow-up was 52 weeks. This is long enough to capture sustained real-world benefit beyond the initial drug effect.

What the data showed

At 52 weeks, tirzepatide-treated participants showed significant improvements over placebo across nearly every patient-reported measure in Study 1. Study 2 showed similar but slightly less consistent results, likely because some participants continued PAP therapy alongside tirzepatide - meaning the placebo arm also received active treatment (the PAP device), compressing the treatment difference.

The key findings:

• PROMIS Sleep Disturbance improved significantly versus placebo in both studies (p < 0.05)
• PROMIS Sleep-related Impairment improved significantly in both studies
• Epworth Sleepiness Scale showed significant reduction in Study 1 (daytime sleepiness decreased substantially); Study 2 showed no significant difference, likely due to ongoing PAP use in that group
• FOSQ Activity-Level domain showed significant improvements - participants were better able to accomplish daily tasks and keep pace with others
• SF-36v2: most health domains improved, including physical functioning and vitality
• EQ-5D-5L Health State Index improved significantly (p < 0.05 in both studies)
• Patient Global Impression: higher proportions of tirzepatide-treated participants reported improvements in fatigue, sleepiness, snoring, and overall sleep quality compared to placebo

The consistency of these improvements across independent measurement tools strengthens the finding considerably. When a drug shows benefit across six different validated PRO instruments, the signal is not an artefact of any single questionnaire.

Why sleep matters so much for GLP-1 users

Sleep apnea affects an estimated 30-40% of people with obesity - and most cases go undiagnosed. Fragmented, poor-quality sleep affects every aspect of metabolism and appetite regulation in ways that actively work against the goals of GLP-1 therapy.

Poor sleep increases ghrelin (the hunger hormone) and decreases leptin (the satiety hormone). It impairs insulin sensitivity. It elevates cortisol, which promotes abdominal fat storage. It reduces the motivation and energy needed to exercise. And it accelerates the muscle loss that GLP-1 medications are already associated with - fragmented sleep disrupts the overnight growth hormone pulses that support muscle protein synthesis.

In other words: if you have untreated sleep apnea and you are on tirzepatide or semaglutide, the sleep disruption is actively undermining the medication's effects on appetite, metabolism, and body composition. Treating the sleep apnea - whether through weight loss, tirzepatide's direct effect, or PAP therapy - removes a major headwind to GLP-1 success.

The tirzepatide FDA approval for OSA in December 2024 was the first time any GLP-1 medication received an indication specifically for a sleep disorder. This reflected the recognition that the weight loss produced by tirzepatide is so substantial (20%+ in many patients) that it physically reduces the amount of pharyngeal tissue collapse that causes apnea events.

The fatigue connection for GLP-1 users without sleep apnea

Fatigue is one of the most commonly reported side effects of GLP-1 medications. Some of it is direct - the nausea and gastrointestinal disruption of the first weeks are genuinely tiring. Some of it is the caloric restriction effect: eating significantly less means less glucose and less dietary fat available for immediate energy use.

But some fatigue on GLP-1 medications comes from nutrient depletion - and this is the part that is most actionable. The nutrients most reliably associated with fatigue in GLP-1 users are:

• Iron - a Harvard Health 2026 meta-analysis of 480,825 GLP-1 users found 64% had insufficient iron levels, and 4% had developed clinical anaemia. Iron is essential for oxygen transport and energy production; deficiency causes a specific, heavy fatigue that does not resolve with sleep
• Vitamin B12 - deficiency causes neurological fatigue - not just tiredness but a general slowness of thinking and movement. Long-term GLP-1 users eating less animal protein are at particular risk
• Magnesium - involved in ATP production (the cellular energy currency); deficiency impairs the energy-generating reactions in every cell in the body. Low magnesium is also associated with poor sleep quality independently of sleep apnea
• Vitamin D - deficiency is associated with fatigue and muscle weakness. GLP-1 users eating less food and spending less time outdoors are at double risk

If you are experiencing persistent fatigue on a GLP-1 medication and do not have a sleep disorder diagnosis, investigating these specific nutrient levels is a logical first step before assuming the fatigue is an unavoidable drug side effect. A targeted supplement protocol that addresses these deficiencies - like GLP-1 Shield, formulated specifically for GLP-1 medication users - is often more effective than a standard multivitamin that is not calibrated to these specific gaps.

Should I get screened for sleep apnea if I'm on a GLP-1 medication?

If you snore loudly, wake feeling unrefreshed, experience excessive daytime sleepiness, or have been told you stop breathing during sleep, yes - get screened. OSA is significantly underdiagnosed, particularly in women (in whom it presents differently than the classic male stereotype), and treating it has meaningful effects on metabolism, energy, and GLP-1 medication efficacy.

If you are on tirzepatide (Mounjaro or Zepbound) and have OSA, the SURMOUNT-OSA data suggests you may be receiving sleep benefit as part of your treatment - not just metabolic benefit. This is worth discussing with your prescriber. Depending on your AHI improvement, it may be possible to re-evaluate whether continued PAP therapy is still required after significant weight loss.

Frequently asked questions

Does tirzepatide help with sleep apnea?

Yes. The FDA approved tirzepatide (Zepbound) for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024. The SURMOUNT-OSA trials showed tirzepatide reduced the apnea-hypopnea index by approximately 55-63% across two studies, and the patient-reported outcomes analysis showed significant improvements in sleep quality, fatigue, and daily functioning over 52 weeks.

Why am I so tired on Ozempic or Wegovy?

Fatigue on GLP-1 medications has several causes: initial GI side effects are tiring, significant caloric restriction reduces available energy, and - most importantly - micronutrient depletion accumulates over months of eating less. Iron deficiency (found in 64% of GLP-1 users in one large meta-analysis), vitamin B12 deficiency, low magnesium, and vitamin D deficiency all cause fatigue independently. Investigating and addressing these deficiencies is the first step before concluding fatigue is an unavoidable drug effect.

Does treating sleep apnea help GLP-1 weight loss work better?

Untreated sleep apnea significantly impairs GLP-1 medication efficacy through multiple pathways: it increases hunger hormones (ghrelin), reduces satiety hormones (leptin), impairs insulin sensitivity, elevates cortisol (which promotes fat storage), and disrupts the overnight hormonal environment that supports muscle maintenance. Treating sleep apnea - whether through weight loss, tirzepatide, or PAP therapy - removes these metabolic headwinds.

What vitamins help with fatigue on GLP-1 medications?

Iron is the most critical, given that 64% of GLP-1 users in a 2026 Harvard Health meta-analysis had insufficient levels. Vitamin B12, magnesium, and vitamin D are also consistently depleted in long-term GLP-1 users and each independently contributes to fatigue. A supplement formulated specifically for GLP-1 users addresses these gaps more precisely than a general multivitamin.